Premium
EFFICACY AND SAFETY OF IBRUTINIB IN COMBINATION WITH RITUXIMAB AS FRONTLINE TREATMENT FOR INDOLENT CLINICAL FORMS OF MANTLE CELL LYMPHOMA. RESULTS OF THE GELTAMO IMCL‐2015 STUDY
Author(s) -
Giné E.,
De la Cruz F.,
Ubieto A. Jiménez,
Jiménez J. López,
GarcíaSancho A. Martín,
Terol M. J.,
GonzálezBarca E.,
Casanova M.,
De la Fuente Burguera A.,
Niebla A. Marín,
Prat A. Muntanola,
GonzálezLópez T. J.,
Aymerich M.,
Setoain X.,
CortésRomera M.,
Rotger A.,
Medina A.,
GarcíaSanz R.,
Campo E.,
LópezGuillermo A.
Publication year - 2021
Publication title -
hematological oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.918
H-Index - 44
eISSN - 1099-1069
pISSN - 0278-0232
DOI - 10.1002/hon.60_2879
Subject(s) - medicine , ibrutinib , mantle cell lymphoma , rituximab , clinical endpoint , phases of clinical research , lymphoma , oncology , surgery , gastroenterology , clinical trial , leukemia , chronic lymphocytic leukemia